Cargando…

Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery

BACKGROUND: We assessed visual residual tumour cells (VRTC) with both Becker’s tumour regression grading (TRG) system and Japanese TRG system in esophageal squamous cell carcinoma (ESCC) patients treated with neoadjuvant therapy followed by surgery. METHODS: We compared Becker system and Japanese sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xingxing, Wang, Hao, Wang, Haixing, Huang, Jie, Wang, Xin, Jiang, Zhengzeng, Tan, Lijie, Jiang, Dongxian, Hou, Yingyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860028/ https://www.ncbi.nlm.nih.gov/pubmed/33535987 http://dx.doi.org/10.1186/s12885-020-07779-0

Ejemplares similares

SOX2 amplification and chromosome 3 gain significantly impact prognosis in esophageal squamous cell carcinoma
por: Wang, Xin, et al.
Publicado: (2021)

Distribution of residual tumors in esophageal squamous cell carcinoma after neoadjuvant PD-1 blockade combined with chemotherapy
por: Jiang, Dongxian, et al.
Publicado: (2023)

Increased MET gene copy number negatively affects the survival of esophageal squamous cell carcinoma patients
por: Wang, Yanqiu, et al.
Publicado: (2019)

The prognostic significance of MCL1 copy number gain in esophageal squamous cell carcinoma
por: Xu, Chen, et al.
Publicado: (2017)

Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2017)

Comparison of the prognostic difference between ypTNM and equivalent pTNM stages in esophageal squamous cell carcinoma based on the 8th edition of AJCC classification
por: Jiang, Dongxian, et al.
Publicado: (2020)

Chromosomal and Genomic Variations in Esophageal Squamous Cell Carcinoma: A Review of Technologies, Applications, and Prospections
por: Song, Qi, et al.
Publicado: (2017)

The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2015)

Independent prognostic role of PD-L1 expression in patients with esophageal squamous cell carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2016)

PMS2 Expression With Combination of PD-L1 and TILs for Predicting Survival of Esophageal Squamous Cell Carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2022)

Pharmacological Inhibition of PP2A Overcomes Nab-Paclitaxel Resistance by Downregulating MCL1 in Esophageal Squamous Cell Carcinoma (ESCC)
por: Song, Qi, et al.
Publicado: (2021)

CDK4 Amplification in Esophageal Squamous Cell Carcinoma Associated With Better Patient Outcome
por: Huang, Jie, et al.
Publicado: (2021)

Identification of clinical prognostic features of esophageal cancer based on m6A regulators
por: Wang, Huimei, et al.
Publicado: (2022)

The efficacy of additional surgical resection after endoscopic resection in pT1b esophageal squamous cell carcinoma: A multi-institutional retrospective study in China
por: Xue, Xuemin, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
por: Zhou, Qing, et al.
Publicado: (2023)

Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial
por: Wang, Hao, et al.
Publicado: (2021)

High amplification of FGFR1 gene is a delayed poor prognostic factor in early stage ESCC patients
por: Song, Qi, et al.
Publicado: (2017)

Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
por: Yin, Jun, et al.
Publicado: (2023)

Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa
por: Gao, Lei, et al.
Publicado: (2022)

A case report of nodal CD4-positive T-cell lymphoproliferative disorder with an indolent course
por: Ge, Xiaowen, et al.
Publicado: (2018)

Characterization of Esophageal Microbiota in Patients With Esophagitis and Esophageal Squamous Cell Carcinoma
por: Jiang, Zongdan, et al.
Publicado: (2021)

Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma
por: Chen, Fei, et al.
Publicado: (2022)

Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma
por: Han, Weiming, et al.
Publicado: (2022)

CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT(3-4a)N(0-1)M(0)) (NCT03001596)
por: Tang, Han, et al.
Publicado: (2017)

Pattern of tumor regression after neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma
por: Li, Bin, et al.
Publicado: (2023)

Publisher Correction: Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
por: Yin, Jun, et al.
Publicado: (2023)

Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment
por: Chen, Weijie, et al.
Publicado: (2021)

The predictive value of microRNAs for pathological response after neoadjuvant treatment in esophageal squamous cell carcinoma: a systematic review
por: Lin, Dong, et al.
Publicado: (2021)

Diagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients
por: Ming, Zizhen, et al.
Publicado: (2014)

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
por: Yang, Weixiong, et al.
Publicado: (2022)

Stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC)
por: Li, Chunguang, et al.
Publicado: (2022)

Histological Regression of Squamous Esophageal Carcinoma Assessed by Percentage of Residual Viable Cells after Neoadjuvant Chemoradiation is an Important Prognostic Factor
por: Tong, Daniel King Hung, et al.
Publicado: (2010)

Integrative proteogenomic characterization of early esophageal cancer
por: Li, Lingling, et al.
Publicado: (2023)

Factors Predicting Effectiveness of Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
por: Ohkura, Yu, et al.
Publicado: (2016)

Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma
por: Wen, Jing, et al.
Publicado: (2022)

Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma
por: Ma, Shaohua, et al.
Publicado: (2018)

Clinical significance of risk stratification of esophageal squamous cell carcinoma after neoadjuvant chemoradiation and surgery
por: Wu, Ya-hua, et al.
Publicado: (2021)

Proteomic analysis reveals key differences between squamous cell carcinomas and adenocarcinomas across multiple tissues
por: Song, Qi, et al.
Publicado: (2022)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study
por: Zhang, Xiaobin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_95qonlftebubpv9d8q8u461lrf